Sarcoma  >>  Recentin (cediranib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

14 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recentin (cediranib) / AstraZeneca
ACTRN12612000020886: A trial of cediranib in the treatment of patients with alveolar soft part sarcoma

Recruiting
2
36
 
The Institute of Cancer Research / Royal Marsden Hospital NHS Foundation Trust (UK), Cancer Research UK, AstraZeneca
Alveolar soft part sarcoma
 
 
NCT00385203 / 2005-005717-38: The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).

Completed
2
35
Europe
AZD2171, cediranib, RECENTIN™
AstraZeneca
Gastrointestinal Stromal Tumors, Soft Tissue Sarcomas
06/08
12/09
NCT00243074: S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery

Checkmark P2 data
Oct 2011 - Oct 2011: P2 data
Completed
2
54
US
cediranib maleate, AZD2171, Recentin, laboratory biomarker analysis
National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
04/10
12/11
NCT00309946: Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery

Checkmark P2 data (Mesothelioma)
Jul 2012 - Jul 2012: P2 data (Mesothelioma)
Checkmark P2 data
May 2011 - May 2011: P2 data
Completed
2
51
US
cediranib maleate, AZD2171, Recentin
National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Epithelial Mesothelioma, Localized Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatous Mesothelioma
09/10
09/10
NCT00305656: AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme

Completed
2
31
US
cediranib maleate, AZD2171, Recentin
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
04/12
 
NCT01062425: Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma

Checkmark P1/2 data-ASCO
Jun 2012 - Jun 2012: P1/2 data-ASCO
Completed
2
261
US
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Placebo Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
National Cancer Institute (NCI), NRG Oncology, Radiation Therapy Oncology Group
Adult Glioblastoma, Adult Gliosarcoma
12/15
05/22
2016-004617-28: Does cediranib together with paclitaxel chemotherapy, or cediranib and olaparib, treat advanced endometrial cancer better than paclitaxel chemotherapy?

Not yet recruiting
2
129
Europe
Olaparib (Lynparza), Cediranib, Paclitaxel, AZD2281, AZD2171, Film-coated tablet, Concentrate for solution for infusion, Olaparib (Lynparza)
The University of Manchester, AstraZeneca Ltd
Advanced or recurrent endometrial carcinoma or carcinosarcoma, Endometrial cancer, Diseases [C] - Cancer [C04]
 
 
NCT00942877: Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma

Checkmark P2 data
Jun 2011 - Jun 2011: P2 data
Checkmark P2 data
May 2011 - May 2011: P2 data
Active, not recruiting
2
53
US
AZD2171, Cediranib
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
09/18
12/24
CASPS, NCT01337401 / 2010-021163-33: A Trial of Cediranib in the Treatment of Patients With Alveolar Soft Part Sarcoma

Unknown status
2
36
Europe, RoW
Cediranib, Placebo
Institute of Cancer Research, United Kingdom, Royal Marsden NHS Foundation Trust
Alveolar Soft-part Sarcoma
07/19
01/20
COPELIA, NCT03570437: Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Active, not recruiting
2
124
Europe
Paclitaxel, L01CD01, Cediranib, AZD2171, 288383-20-0, Olaparib, AZD2281, Lynparza, L01XX46
University of Manchester, AstraZeneca, Cardiff University
Carcinosarcoma, Endometrial Neoplasms
01/23
06/23
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
NCT01391962: Sunitinib or Cediranib for Alveolar Soft Part Sarcoma

Active, not recruiting
2
34
US
Cediranib, Sunitinib
National Cancer Institute (NCI)
Sarcoma, Alveolar Soft Part
11/23
03/25
NCT00662506: Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma

Completed
1/2
46
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Diffusion Tensor Imaging, DTI, Diffusion Weighted Imaging, Diffusion Weighted MRI, Diffusion-Weighted Magnetic Resonance Imaging, Diffusion-Weighted MR Imaging, Diffusion-Weighted MRI, DWI, DWI MRI, DWI-MRI, MR Diffusion-Weighted Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, DCE MRI, DCE-MRI, DYNAMIC CONTRAST ENHANCED MRI, Fludeoxyglucose F-18, 18FDG, FDG, fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, magnetic resonance perfusion imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET SCAN, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
04/14
04/14
SWOG S0905, NCT01064648: Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Active, not recruiting
1/2
117
US
Cediranib Maleate, AZD2171, AZD2171 Maleate, Recentin, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Placebo Administration
National Cancer Institute (NCI)
Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Sarcomatoid Mesothelioma
06/18
03/25

Download Options